all report title image
  • Published On : Nov 2022
  • Code : CMI4062
  • Industry : Pharmaceutical
  • Pages : 201
  • Formats :

Somatropin is a recombinant human growth hormone indicated for the treatment of growth hormone deficiency in children and adults, as well as Turner syndrome, Prader-Willi syndrome, Chronic Renal Insufficiency (chronic kidney disorder), and others. Somatropin stimulates linear growth (height), tissue growth, and lipid, protein, carbohydrate, and mineral metabolism. Injections of somatropin are used to treat growth hormone insufficiency in both adults and children. Growth hormone is a natural hormone produced by the body. Children with specific diseases  such as Growth hormone deficiency (GHD),that hinder normal growth and development can potentially benefit from somatropin injections to accelerate their growth. In addition to being available as a powder in vials and cartridges to be combined with liquid and administered subcutaneously, somatropin injection is also available as a solution (liquid) in prefilled dosing pens and cartridges (under the skin). Adults often receive a somatropin injection once a day to replenish growth hormone. In individuals with human immunodeficiency virus (HIV) who have HIV-associated wasting syndrome, somatropin injection (Serostim) is used to enhance body weight and physical endurance. Injections of somatropin (Zorbtive) are used to treat growth hormone deficiency.

Global Somatropin Market is estimated to be valued at US$ 3.6 Bn in 2022 and is expected to exhibit a CAGR of 7.2% over the forecast period (2022-2030).

Figure 1: Global Somatropin Market Share (%) Analysis, By Dosage Form, 2022

Somatropin  | Coherent Market Insights

Global Somatropin Market – Drivers

Product approval from regulatory authorities such as ANVISA (National Sanitary Surveillance Agency), for drugs of Somatropin is expected to drive growth of the global somatropin market over the forecast period.

Product approval from regulatory authorities such as ANVISA (National Sanitary Surveillance Agency), for drugs of Somatropin is expected to drive growth of the global somatropin market over the forecast period. For instance, in May 2019, ANVISA (National Sanitary Surveillance Agency), approved the biosimilars named Criscy (Somatropin), which is safe and effective in the treatment of patients with pathologies associated with growth hormone deficiency. Criscy (Somatropin) is manufactured by Cristalia, a pharmaceutical & biotechnological research and development company, which is headquartered in Sao Paulo, Brazil.

Increasing long term effect of growth hormone therapy on children with growth hormone deficiency is expected to drive the global somatropin market growth over the forecast period.

Increasing long term effect of growth hormone therapy on children with growth hormone deficiency is expected to drive the global somatropin market growth over the forecast period. For instance, according to the data published in the Journal Acta Biomedica, in 2020, a study was conducted among 252 short children with growth hormone deficiency, 63 with idiopathic short stature, 26 with small for gestational age, and 9 with Turner syndrome who were treated in King Abdullah International Medical Research Center, Jeddah, Saudi Arabia with growth hormone in 2018.

CMI table icon

Somatropin Market  Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 3.6 Bn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 7.2 % 2030 Value Projection: US$ 6.3 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Dosage Form: Powder, Solvent
  • By Application: Grwth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, AnkeBio Co. Ltd., Reliance Life Sciences, GeneScience Pharmaceuticals, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., and USV Limited

Growth Drivers:
  • Product approval from regulatory authorities
  • Increasing long term effect of growth hormone therapy on children with growth hormone deficiency
Restraints & Challenges:
  • Increasing presence of alternative drugs for growth hormone deficiency

Global Somatropin Market- Impact of the Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.

The COVID-19 pandemic has affected clinical trials drastically. For instance, on April 23, 2020, according to a survey conducted by Medidata Solutions, Inc., a company which markets and develops software as a service for clinical trials, conducted a survey which showed observations such as 63% of survey respondents reported that they had stopped recruiting new patients for ongoing clinical trials and 43% of the respondents had postponed their studies.

Moreover, since the COVID-19 virus outbreak in December 2019, the supply chain of growth hormone deficiency drugs was hampered and the somatropin market was affected in a negative way, however the market recovery was seen over the late phase of COVID-19.

Global Somatropin Market– Restraints

Increasing presence of alternative drugs for growth hormone deficiency is expected to hamper growth of the Global Somatropin Market over the forecast period.

For instance, according to the data published in the biostation which provides information about scientific data where in 2022, Sermorelin therapy is less expensive than human growth hormone treatment, sometimes by as much as 10%. Injection or a multi-dose auto pen are two alternatives for administration of drug.

Global Somatropin Market– Regional Analysis

On the basis of region, the Global Somatropin Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, Europe market is expected to witness significant growth, owing to key companies in market focusing on research and development activities for drug development for treatment indicated for Pediatric Growth Hormone Deficiency. For instance, on June 12, 2022, Novo Nordisk A/S, a global healthcare company headqutered in Denmark announced results of once-weekly Sogroya (somapacitan) injection in helping children achieve growth targets of annualized height velocity (AHV).1 The phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented at the Endocrine Society’s Annual Meeting (ENDO 2022) in Atlanta, Georgia (U.S.).

Figure 2: Global Somatropin Market Value (US$ Bn), by Region, 2022

Somatropin  | Coherent Market Insights

Global Somatropin Market– Key Players

Major players operating in the Global Somatropin Market include Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, AnkeBio Co. Ltd., Reliance Life Sciences, GeneScience Pharmaceuticals, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., and USV Limited.

Somatropin injection is used to replace growth hormone (a natural hormone produced by body) in adults and children with growth hormone deficiency. Somatropin injection is also used to increase growth in children with certain conditions that affect normal growth and development. Somatropin injection comes as a solution (liquid) in prefilled dosing pens and cartridges and also as a powder in vials and cartridges to be mixed with liquid to be injected subcutaneously (under the skin). When somatropin injection is given to replace growth hormone in adults, it is usually given once a day. Somatropin injection (Serostim) is used to increase body weight and physical endurance in patients with human immunodeficiency virus (HIV) who have HIV-associated wasting syndrome. Somatropin injection (Zorbtive) is used to treat short bowel syndrome in adults who are receiving additional nutrition or fluids from intravenous (IV) therapy. Somatropin is a human growth hormone (hGH) analog. It works by replacing growth hormones that are normally produced in the body, which may result in increased growth, body weight, and improved absorption of nutrients and fluids from the intestines.

Market Dynamics

Increasing product approval by regulatory authorities is expected to fuel growth of the global somatropin market over the forecast period. For instance, on January 13, 2022, Ascendis Pharma A/S, a company that manufactures pharmaceutical products announced that the European Commission (EC) granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name TransCon hGH) as a once-weekly subcutaneous injection for the treatment of children and adolescents aged 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone (also known as growth hormone deficiency, or GHD). TransCon hGH is a prodrug of somatropin that provides sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body.

Key features of the study:

  • This report provides an in-depth analysis of the global somatropin market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global somatropin market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, AnkeBio Co. Ltd., Reliance Life Sciences, GeneScience Pharmaceuticals, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., and USV Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global somatropin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global somatropin market

Detailed Segmentation:

  • Global Somatropin Market, By Dosage Form:
    • Powder
    • Solvent
  • Global Somatropin Market, By Application :
    • Growth Hormone Deficiency (GHD)
    • Turner Syndrome
    • Chronic Renal Insufficiency
    • Prader Willi Syndrome
    • Small for Gestational Age
    • SHOX Deficiency
    • Others
  • Global Somatropin Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Somatropin Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Novo Nordisk A/S *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Pfizer, Inc.
    • Eli Lilly and Company
    • GeneScience Pharmaceuticals
    • Sandoz International GmbH
    • Ipsen Pharma
    • LG Chem
    • Merck KGaA
    • Genentech, Inc.
    • Ferring B.V.
    • AnkeBio Co., Ltd
    • USV Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global Somatropin Market is expected to exhibit a CAGR of 7.2% during the forecast period (2022-2030).
 The Market is estimated to be valued at US$ 3.6 Bn in 2022.
Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, AnkeBio Co. Ltd., Reliance Life Sciences, GeneScience Pharmaceuticals, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., and USV Limited are some of the prominent players operating in the market.
The market is expected to be valued at US$ 6.3 Bn in 2030.
Europe is the prominent region in the market.
Solvent, which belongs to the type segment, is the prominent segment in the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo